Sorafenib: in hepatocellular carcinoma

Drugs
Dene Simpson, Gillian M Keating

Abstract

Sorafenib is an orally active multikinase inhibitor with anti-tumour activity. It was recently approved in the US and the EU for the treatment of patients with hepatocellular carcinoma. Oral sorafenib 400 mg twice daily significantly improved survival in patients with advanced hepatocellular carcinoma in the randomized, double-blind, multicentre, phase III SHARP trial (n = 602); the median duration of survival was 10.7 months with sorafenib and 7.9 months with placebo. In addition, the median time to progression was significantly longer in patients receiving sorafenib than in those receiving placebo (5.5 vs 2.8 months). Combination therapy with oral sorafenib 400 mg twice daily and intravenous doxorubicin has potential in the treatment of patients with advanced hepatocellular carcinoma, according to the results of a randomized, double-blind, phase II study (n = 96). Although the addition of sorafenib to doxorubicin did not significantly delay the time to progression, the median durations of overall survival and progression-free survival were significantly longer with sorafenib plus doxorubicin than with doxorubicin alone. Monotherapy with oral sorafenib 400 mg twice daily was generally well tolerated in patients with advanced h...Continue Reading

References

Sep 1, 2005·Cancer Chemotherapy and Pharmacology·Chetan LathiaPavur Sundaresan
Feb 28, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H RichlyD Strumberg
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Oct 4, 2006·Nature Reviews. Drug Discovery·Scott WilhelmSusan Kelley

❮ Previous
Next ❯

Citations

Mar 29, 2016·Cancer Science·Masamitsu TanakaNamiko Aiba
Feb 13, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Paz de la TorreAna I Flores
Oct 18, 2008·Expert Review of Anticancer Therapy·Katerina Malagari
Dec 7, 2019·Expert Opinion on Drug Discovery·Qiuzi DaiYuyang Jiang
Jun 9, 2017·International Journal of Molecular Sciences·Tzu-Ting HuangKuen-Feng Chen
Apr 14, 2018·Pediatric Hematology and Oncology·Helen PearsonFernando Carceller
Mar 19, 2020·Pediatric Hematology and Oncology·Helen PearsonFernando Carceller
Jul 23, 2009·Proceedings of the National Academy of Sciences of the United States of America·Byoung Kwon YooDevanand Sarkar
Jan 14, 2011·Expert Opinion on Pharmacotherapy·Yong-Song Guan, Qing He
Aug 30, 2008·Der Radiologe·M-K GantenT M Ganten
Feb 18, 2009·The Journal of Clinical Investigation·Byoung Kwon YooDevanand Sarkar
Sep 10, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tanios Bekaii-SaabMiguel Villalona-Calero
Feb 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T PressianiA Santoro
Aug 30, 2008·Drug Discovery Today·Luigi FiumeGiuseppina Di Stefano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.